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Nonheart-beating kidney donation: Current practice and future Renal transplant activity is of the order of 1800 per
developments. year in the United Kindom and there were 4831 people
Background. Nonheart-beating kidney donation (NHBD) awaiting kidney transplantation at the end of Augustis gaining acceptance as a method of donor pool expansion.
2001 (United Kingdom transplant data). This shortfallHowever, a number of practitioners have concerns over rates
in kidneys is exacerbated by two trends decreasing theof delayed graft function, acute rejection, and long-term graft
survival. The ethical issues associated with NHBD are complex number of available brain stem–dead (heart-beating) do-
and may be a further disincentive. Tailored strategies for pres- nors. These are a reduction in fatal road traffic accidents
ervation, viability prediction, and immunosuppression for kid- and a decline in the number of deaths from intracerebral
neys from this source have the potential to maximize the num-
hemorrhage. On top of the decrease in available organsber of available organs. This review article presents the current
is a constant expansion in the number of potential recipi-practice of NHBD kidney transplantation, examines the results
ents [1]. There is, therefore, a continuing challenge toand draws comparisons with cadaveric kidneys, and explores
some areas of potential development. maximize donor organ availability. One approach for re-
Methods. A review of the current literature on NHBD kid- ducing the discrepancy between required and available
ney donation was performed. kidneys for transplantation is the use of nonheart-beat-Results. The renewed interest in NHBD kidneys is driven
ing donors (NHBD). This paper presents the currentby a continuing shortfall in available organs. Those centers
practice of NHBD kidney transplantation and exploresinvolved in NHBD report an increase in kidney transplants of
the order of 16% to 40% and there is no evidence that the some of the areas of potential development.
financial costs are higher with NHBDs. The majority of experi-
ence comes from Maastricht category 2 NHBDs, where an
estimation of warm time is possible. This is generally limited DEFINITION OF NHBD KIDNEYS
to 40 minutes. There are variations in the technique for kidney
The distinction between heart-beating donors (HBDs)preservation prior to retrieval, but most centers use an aortic
and NHBDs lies in the criteria used to diagnose death;balloon catheter. Much work has looked at the ideal technique
in HBDs brain-stem death criteria are used, whereasfor kidney preservation prior to implantation. Evidence sug-
gests that machine perfusion produces the best initial function cardiac criteria are applied to NHBDs (Table 1) [2].
rates, decreased use of adjuvant immunotherapy and fewer NHBD kidneys suffer a period of warm ischemic dam-
haemodialysis sessions than static cold storage. age [the warm ischemic time (WIT)], calculated as theConclusion. Despite being associated with poorer initial
time between cardiopulmonary arrest and initiation ofgraft function, the long-term allograft survival of NHBD kid-
external cardiac massage with artificial ventilation. It isneys does not differ from the results of transplantation from
cadaveric kidneys. Further, serum creatinine levels are gener- often of unknown duration and is a damaging period
ally equivalent. Constant reassessment of the ethical issues is since there is no perfusion to support renal cell homeo-
required for donation to be increased while respecting public stasis. The use of NHBD is not new; prior to brain-stemconcerns. Use of viability assessment and tailoring of immune
death legislation, kidneys from NHBD were routinelysuppression for NHBD kidneys may allow a further increase
retrieved as the only organ resource. In those countriesin donation from this source.
such as Japan, where brain-death criteria are not gener-
ally accepted [3] and organ procurement from HBDs is
Key words: nonheart-beating kidney donation, heart-beating donors legally prohibited without the patient’s written consent
before brain death [4], NHBDs are still the major source
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Table 1. Brainstem and cardiac criteria for diagnosis of death
Criteria for brainstem death (HBD)
• The underlying pathologic lesion should be understood;
• There should be no pharmacologic, metabolic, or hormonal influence;
• Pupillary, corneal, occulocephalic, vestibulo-occular, and gag reflexes should be absent;
• No pain response to stimulation in the distribution of the fifth cranial nerve; and
• A rebreathing test with 100% oxygen should be delivered to maintain satisfactory oxygenation, while ventilation is switched off. The rise
in arterial pCO2 should not stimulate respiration.
These tests are performed by two experienced clinicians on two separate occasions.
Criteria for cardiac death
The criteria for brain-stem death need not be fulfilled for nonheart-beating donation (NHBD) candidates. When cardiac arrest has occurred
and the medical team has decided that further treatment is pointless, then the diagnosis of death is simple. The criteria are:
• Deep coma
• Absence of pulse
• ECG evidence of asystole
Cardiac death in the context of potential organ donation is defined as occurring after 30 minutes of unsuccessful cardiopulmonary resuscitation (CPR)
under hospital conditions. Resuscitation must include external cardiac massage, intubation, ventilation, defibrillation (if indicated), and appropriate
intravenous medication. “Unsuccessful” means that these measures did not achieve spontaneous contractile cardiac activity or peripheral circulation.
meet demand. A number of centers are now involved although there is considerable variation in WIT because
of the heterogeneity of the group. Other sources includein NHBD transplantation but many transplant physicians
are reluctant to use such kidneys; the concerns include patients suffering isolated brain injury, anoxia and stroke,
and victims of major trauma who die soon after hospitalhigh rates of delayed graft function, poor renal function,
increased expense secondary to greater medication, dial- admission [9]. Category 3 encompasses patients who are
dying, often on an intensive care unit. These were theysis use, longer hospital stay, and alleged inferior graft
survival rates compared to HBD. The extent of these traditional donors prior to introduction of brain-death
legislation, and still account for a greater proportion ofconcerns was highlighted in a questionnaire on the need
to take specific consent from recipients of NHBDs; half donors in the United States than in other countries. The
family will have agreed to organ donation, and afterof the transplant surgeons questioned thought that a
NHBD kidney increased the risk of transplantation, 29% medical support is withdrawn, cardiac arrest is awaited.
A double-balloon triple-lumen (DBTL) perfusion cathe-thought it did not, and 21% were unsure [6].
There is an important distinction between controlled ter (see later discussion) is introduced 2 to 10 minutes
after the patient is declared dead by cardiac criteria. Theand uncontrolled NHBD. Controlled NHBD are those
in whom cardiac arrest is awaited by the transplant team; main ethical issue in this category is that the decision to
donate occurs before the patient is dead.ischemic time is kept short and other organs may be
harvested along with the kidney. Uncontrolled NHBD Category 4 comprises patients who suffer unexpected
cardiac arrest during or after determination of brain death.are those donors who suffer cardiac arrest suddenly be-
fore scheduled organ harvesting can be arranged [7];
NHBD contribution to the donor poolhence, the WITs are longer. At the First International
Workshop on NHBD in Maastricht, four categories of The most encouraging figure for the contribution of
NHBD kidneys to transplant programs has come fromNHBD were described [8], both to aid legal and ethical
discussion and to highlight possible differences in viabil- Daemen et al [10], who reported 40% of their kidneys
were accounted for by NHBDs. However, due to fasterity. Category 1 includes the victims of accident and sui-
cide (some centers exclude suicide victims from their decreases in the supply from other sources, this 40%
contribution did not increase the overall transplant activ-programs) who are found dead at the scene and resuscita-
tion is deemed pointless (e.g., fatal cervical spine frac- ity. For the Leicester group, Varty et al [11] reported
38% of donors were NHBD for the first year of useture). Problems with using this group as donors are un-
known WIT and difficulty in contacting relatives quickly of this resource, and later Nicholson [12] reported that
NHBD accounted for 21% of total transplants. Increasedenough for consent. There is little experience of using
category 1 donors reported in the literature. Category 2 transplant activity of 20% [13] and 16% [8] have also
been reported. Light et al [14] stated that the numberdonors are the mainstay of the NHBD pool in Europe
and Japan, and are mostly victims of sudden cardiac (the of NHBD opportunities equals that of HBD, but others
have suggested that there are twice as many potentialmajority) or cerebral catastrophe who are brought to
emergency departments while being resuscitated by am- NHBDs as there are HBDs [15]. Terasaki, Cho, and
Checka [16] claim that if all potential NHBD kidneysbulance personnel or who die in the department. An
estimation of WIT is easier because the personnel are were retrieved, waiting lists for kidney transplants would
be eliminated. Further, they suggested that there wouldable to provide information on the time of collapse,
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Fig. 1. The number of renal transplants performed in a 10-year period
in Leicester, by donor source [18]. Symbols are: ( ), live donors; (),
nonheart-beating donors (NHBD); (), heart-beating donors.
be no need to use living donors, thereby avoiding expo-
sure of otherwise healthy individuals to potential mor-
bidity. In a retrospective review of 603 in-patient hospital
deaths, Daemen et al [17] found that utilization of this
resource would have yielded up to 56 NHBDs, increasing
transplant activity 4.5-fold.
Workload and Costs generated by a NHBD program
Figure 1 shows the contribution by donor type for the
Leicester transplant program. The figures for 1992 to
Fig. 2. The in situ perfusion technique showing correct positioning of2000 show a total of 350 kidney transplants performed;
the double-balloon triple-lumen (DBTL) catheter in the aorta, inflated77 (22%) kidneys came from NHBDs, 224 (64%) from balloons and perfusion fluid attached to the catheter. The femoral vein
HBDs, and 49 (14%) were from live donors [18]. In the is vented.
3-year period, 1992 to 1995, the authors’ unit had 73
NHBD referrals (146 potential kidneys), with 38 kidneys
(26%) retrieved [19]. This is a sizable workload, with
tential NHBDs. A checklist (Table 2) is used by the re-considerable costs implications.
sponsible physician (usually an emergency departmentMaintaining a patient on hospital dialysis per year
registrar or consultant) to ensure that the donor is eligible.costs £25,000 to £31,000, with home dialysis estimated
If there are no exclusion criteria, the transplant coordina-at £16,000 to £25,000, depending on region. The cost of
tor is notified and the transplant team attends. The teama renal transplant procedure is approximately £14,500,
consists of the transplant coordinator, consultant, andand the annual maintenance cost posttransplant is £6500
(1998 figures, Department of Health NHS Renal Pur- registrar. The donor is left for a 10-minute period from
chasing Guidelines data), an obvious considerable an- the time of pronouncement of cardiac death to ensure
nual saving over dialysis. Thus, the more patients than brain death. This length of time has been a topic for debate
can be converted from dialysis to transplantation, the (see later discussion). After this period, the donor is placed
greater the cost savings. For immunosuppression, the on the mechanical external compression and artificial
costs are equal for HBDs and NHBDs, as similar regi- ventilation machine [20], a device originally developed
mens are used regardless of donor source. The cost rises to assist with cardiopulmonary resuscitation (CPR). It
significantly if acute rejection episodes are treated with provides external cardiac compressions at a set rate and
immunoglobulins, but the evidence (see later discussion) depth, along with artificial ventilation with 100% oxygen
suggests there is no difference in acute rejection rates via an endotracheal tube, with the aim of limiting isch-
between HBDs and NHBDs. emic damage to the kidneys. No further action is taken
until consent for placement of femoral artery and vein
METHODS AND TECHNICAL ASPECTS: catheters is given by relatives. Once consent is obtained
THE LEICESTER APPROACH (75% to 80% of potential donors [10, 20]) a right groin
crease incision is made and the common femoral artery isAll patients who have sustained, or are likely to sus-
tain, permanent circulatory arrest are considered as po- isolated and controlled. Through a transverse arteriotomy,
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Table 2. The exclusion criteria for NHBDs [19, 20]
1. Cardiac and circulatory arrest does not last longer than 40 minutes
(varies between centers). This is the period of absolute circulatory
arrest and does not include periods of resuscitation.
2. The patient is between 16 and 60 years old.
3. The patient does not belong to a high-risk group for human immuno-
deficiency virus (HIV), or hepatitis B or C infection. There should be
no signs of intravenous drug abuse.
4. The patient has no history of primary kidney disease, uncontrolled hy-
pertension, or complicated insulin-induced diabetes mellitus (IDDM).
There are no signs of intravascular coagulation with anuria and no signs
of malignancy other than a primary (nonmetastatic) cerebral tumor.
5. There are no signs of sepsis or serious infection.
6. Patients who have died after assisted suicide or euthanasia are ex-
cluded from some protocols.
(Figs. 2 and 3). Again, this gives indirect evidence of perfu-
sion and, if the catheter is incorrectly placed, it can be
repositioned [22]. A misplaced catheter most commonly
occurs if the caudal balloon is pulled back too far; in
this circumstance the contralateral leg will be perfused
and feel cold. During the procedure, the transplant coor-
dinator will reapproach the family members and ask for
consent for the donation of kidneys, corneas, bones, and
heart valves. Prior to transfer to theater for donor ne-
phrectomy, the family members are offered the opportu-
nity to see the body, and the coroner and coroner’s pa-
thologist are consulted. We attempt to complete the donor
nephrectomy within 2 hours of commencement of in situ
perfusion. Further in-depth description of the technique
is given by Heineman, Daemen, and Kootstra [23].
Fig. 3. A check radiograph showing correct positioning of the double-
balloon triple-lumen (DBTL) catheter. The balloons are filled with dilute WIT and time limits
contrast.
The length of the WIT correlates well with graft dam-
age and there is a point at which organs become nonvia-
ble. Although there is no strict maximum WIT or in situthe DBTL catheter is inserted into the aorta [21]. The
caudal-most (abdominal) balloon is inflated with dilute perfusion time, some guidelines have been suggested,
and these reflect estimates of the amount of reversiblecontrast, and the catheter is pulled back until it lodges
at the aortic bifurcation. The cranial-most (thoracic) bal- damage the kidney can tolerate. Limits of 30 minutes
[24], 35 minutes [25], and 45 minutes [26] have beenloon is then inflated with contrast and 150 mL blood is
withdrawn for virology, syphilis serology, blood group- advocated. Functional recovery in animal models has
been achieved after much greater WITs (e.g., 120 min-ing, and tissue typing. The catheter is then connected
to the cold (4C) perfusion fluid reservoir, and in situ utes [24, 27] and 140 minutes [28, 29]). In practice, allow-
able maximum WITs vary in a qualitative manner, forperfusion is started with hyperosmolar citrate solution.
Heparin and phentolamine are administered in the first example, a young and previously fit donor may be al-
lowed a longer WIT than an older donor.bag of preservation fluid. Heparin is thought to reduce
intravascular thrombosis, and phentolamine may reduce
Low yield of NHBD kidneysintrarenal vasospasm. The femoral vein is controlled, and
a 14 Ch urinary catheter is inserted to vent the circulation. There is a low yield of useable kidneys from NHBDs.
Over a 3-year period at the authors’ unit there were 73A typical volume of perfusion fluid used is 10 to 15 L.
Assessment of adequacy of in situ perfusion is difficult; referrals, giving 146 potential kidneys. The retrieval rate
was 24 of 73 (33%). The reasons for this low rate wereduring perfusion, the flanks can be palpated to assess
temperature and there is indirect evidence of kidney per- analyzed, and included refused consent (N  13), rela-
tives unavailable for consent (N 4), technical problemsfusion if the flanks are cold. Further evidence of correct
placement is gained if the venous outflow clears as it (N 10), long asystolic period (N 8), medically unsuit-
able donor (N  8), and unavailability of transplant staffbecomes diluted with perfusion fluid. A check radiograph
of balloon position is taken to confirm correct placement (N  1).
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Table 3. A comparison of rates of PNF, DGF, and acute rejection at five centers performing non-heart beating kidney (NHBD) transplantation
Nicholson [38] Ohshima [39] Tanabe [40] Cho [15] Wijnen [35]
Primary nonfunction (PNF) 9% 4% 9% 4% 14%
Delayed graft function (DGF) 84% 70% 78% 48% 60%
Acute rejection 29% 45% 51% 19% 48%
Comparisons should be made with caution due to variations in donor category, perfusion techniques, human leukocyte antigen (HLA) matching and immunosuppres-
sion protocols.
Of a potential 48 kidneys, 44 were obtained and 38 of Shiroki et al [41] claimed that the PNF rate is highest
in those NHBD kidneys with a history of WIT longerthese suitable 44 kidneys were transplanted, giving a
ratio of actual transplants to total number of kidneys than 30 minutes. Tanabe et al [40] disagreed, stating that
length of WIT had no relationship to the rates of PNF,theoretically available as 38 of 146 (26%) [19].
but no WIT was longer than 30 minutes in their study.
Do NHBD kidneys function as well as HBD kidneys? In HBDs, PNF is most often due to the vascular compli-
cations of arterial or venous thrombosis, and one studyIschemic damage to NHBD kidneys. Central to the
debate over the safety and efficacy of NHBD kidney use has shown no significant difference in the rates of vascu-
lar thrombosis (1%) when comparing NHBD and HBDis whether warm ischemic damage causes unacceptable
levels of irreversible kidney damage. Consideration must [38]. The potential role of viability testing prior to im-
plantation is discussed later.be given to the effect of warm ischemic damage on rates
of primary nonfunction (PNF), delayed graft function Rates of DGF. Almost all authors find the rate of
DGF higher with NHBD kidneys. DGF occurs in 20%(DGF), acute and chronic rejection, patient and allograft
survival, renal function, and quality of life. to 60% of HBD kidney transplants [14, 31, 32, 35] and
50% to 100% of NHBD transplants [36, 40] (Table 3).When considering the results of NHBD kidneys, it is
important to differentiate between different categories, This higher rate of DGF in NHBD kidneys is likely
to be a consequence of marked acute tubular necrosisas the warm times can differ greatly. In a retrospective
study of category 3 and 4 donors (in which the preagonal secondary to the long WIT. Not all DGF is due to acute
tubular necrosis, although acute tubular necrosis is thephase may be prolonged), Rowinski et al [30] concluded
that events around the time of brain-stem death such as most common cause and it is, therefore, unsurprising
that kidneys harvested from NHBDs have a higher inci-profound metabolic, hemodynamic, and hormonal changes
may play a more important role in the pathogenesis of dence of acute tubular necrosis than those from a HBD
[34]. It is important to note that WIT is not the onlyrenal damage than warm ischemia. Alvarez et al [31]
showed that kidneys from ITU-based NHBD had poorer variable determining the likelihood of DGF; Yokoyama
et al [42] found that long duration of pretransplant recipi-short- and long-term function, and were associated with
a greater rate of PNF than NHBD kidneys procured ent dialysis and increased body weight were also corre-
lated with posttransplant early graft dysfunction.from the emergency department, and this was strongly
associated with periods of hypotension prior to retrieval. Schlumpf et al [43] reported similar results for NHBD
and HBD for rates of acute tubular necrosis and 1-yearMoreover, White et al [32] describe a series of transplants
in which, despite higher levels of DGF (93% NHBD graft survival if WIT was kept to less than 20 minutes.
These donors, however, had a lower mean age (35 years)and 17% of cadaveric), graft survival at 3 years was
significantly better for NHBDs than HBDs (84% vs. than other groups, which may have skewed their findings.
Another point, previously mentioned, is that the insults73%). One explanation for this is that the NHBD kidneys
were not subjected to the harmful events associated with suffered by HBD kidneys (the profound metabolic and
hormonal changes associated with brain-stem shock)brain-stem death. A pathophysiologic explanation for
this phenomenon was proposed by Takada et al [33], may be as significant in the long-term as the warm isch-
emic damage suffered by NHBD kidneys.where the up-regulation of genes for proinflammatory
mediators was demonstrated in an animal model of Rates of acute rejection. During and after recovery
from DGF, it has been postulated that kidneys sufferbrain-stem death. It is postulated that if these results are
relevant to humans, then organs from HBDs will be more frequently from acute rejection; the proposed
mechanism is up-regulation of human leukocyte antigenmore prone to early host inflammatory and immune re-
sponses, as NHBDs suffer sudden circulatory arrest, (HLA) class II antigens during DGF. The literature sug-
gests this is true for HBD, but it does not seem to holdwhich allows no time for gene up-regulation.
Rates of PNF. The rate of PNF of NHBD kidneys true for NHBDs [35, 44, 45]. Equivalent acute rejection
figures for NHBDs and HBDs have been reported byranges from 8% to15% [11, 34, 35], which is higher than
the 2% to 5% quoted for HBD kidneys [36, 37] (Table 3). many authors [34, 46–48]. Only one large comparative
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Fig. 4. Posttransplant serum creatinine by donor source [35]. Symbols are:
( ), heart-beating donors (HBD); (), nonheart-beating donors (NHBD).
Serum creatinine is presented as mean  standard deviation of the mean.
study [15] shows higher acute rejection rates for NHBDs
(19%) compared to HBDs (14%), but it is not clear if
the statistical significance has clinical relevance.
Rates of chronic rejection. There is a paucity of data
on chronic rejection rates in NHBDs. The process of
chronic rejection is poorly understood, but seems multi-
Fig. 5. (A) Representation of renal allograft survival from heart-beatingfactorial with a final common pathway of a stereotyped (HBD) and nonheart beating (NHBD) donors from Eurotransplant data
response of the kidney to early injury. Thus, the warm [35]. (B) Representation of renal allograft survival from heart-beating
(HBD) and nonheart beating (NHBD) donors from the Kidney Transplantischemic damage suffered by NHBD may theoretically
Registry of the United Network for Organ Sharing [15].augment chronic rejection, either in pace or frequency.
The only comparative study of HBDs and NHBDs, with
a follow-up period of 95 months, showed no difference
in chronic rejection rates [36]. On balance, the literature seems to suggest that during
Renal function. There is disagreement in the literature the first month posttransplant, serum creatinine is rela-
over how effectively NHBD kidneys function. Some tively high in NHBD kidneys, but this improves with
studies show they can achieve early serum creatinine time as the renal tubular epithelium is regenerated (Fig. 4).
levels in the normal range [11, 15, 37, 49, 50], while others Renal allograft survival. Despite the poorer graft func-
illustrate poorer graft function in both the short- and tion of NHBD kidneys in the early posttransplant period,
long-term [51, 52]. Castelao et al [34] found that for the majority of data show no significant differences in
up to 1 year, serum creatinine is significantly higher in allograft survival between NHBD and HBD kidneys at
NHBDs than HBDs, but from then, until 6 years (the 3 years [15], 5 years [15, 40], and 10 years after trans-
end of the study), the difference disappears. Others have plantation [35] (Fig. 5). An in-depth review of 24 years
confirmed this; in the medium term, NHBD kidneys experience of NHBD and HBD kidneys again revealed
achieve a good level of renal function with a mean serum no difference in graft survival [54]. The influence of WIT
creatinine at 12 months of 174 mol/L [53] and a median on NHBD kidney graft survival was investigated by
of 199 mol/L at 18 months [11]. These figures are com- Morpurgo, Rigotti, and Ancona [27], who found a de-
parable to HBD kidneys. Other investigators have shown crease in graft survival with increasing ischemic time.
significantly higher serum creatinine for NHBDs com- Others have found that length of ischemic time does not
pared to HBDs. In one report [18], NHBD kidneys gave influence rates of graft loss [40, 52, 55]. It would seem,
consistently higher creatinine levels (on the order of 40 then, that long ischemic time causes reversible graft
to 50 mol/L) over 5 years compared to HBD kidneys. problems at an early stage, in terms of PNF and DGF.
However, these levels were stable and not rising. The Later, NHBD grafts appear to perform as well as those
implication is that NHBD kidneys have a reduced func- from HBDs. NHBD kidneys meet The British Trans-
tioning glomerular mass due to initial ischemic damage, plantation Society guidelines [56] for allograft survival
but once transplanted there is no evidence of further at 1 and 5 years of 80% and 60%, respectively. This has
obvious relevance to NHBD programs and is evidencedeterioration up to 5 years.
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alone conferred any significant effect on the ability of
renal vasculature to relax after a constricting stimulus.
However, the two combined insults resulted in loss of
endothelial cell function. There are clinical data to sup-
port this idea. First, cold ischemia is more damaging
when superimposed on a period of warm ischamia, in
terms of reduction in subsequent renal function [58].
Second, when comparing kidneys with WIT less than 45
minutes plus a cold ischemic time of less than 22 hours
or longer than 22 hours, the 5-year survival rate is signifi-
cantly worse for those with the longer cold time [59].Fig. 6. Quality-of-life scores for end-stage renal failure (ESRF) and trans-
The preservation fluids used to limit ischemic damageplant recipients according to source, using KD-QOL SF36 scoring system.
Abbreviations are: NHBD, nonheart-beating donors; HBD, heart-beating include EuroCollins (EC), University of Wisconsin (UW)
donors; LD, live donors [18]. histidine-trytophan-ketoglutarate (HTK) [60], and cel-
sior solution [61, 62], discussed below.
EuroCollins solution (EC) and University of Wisconsin
solution (UW). A randomized, controlled trial of UWthat the widespread reluctance to accept NHBD kidneys
versus EC for NHBD kidneys showed no difference inas a valid source of donor kidneys may be misplaced.
delayed graft function rates between the groups [63],Patient survival and quality of life. Published data
despite other data that show that UW is superior toshow no difference in patient survival in NHBD and
EC in reducing the incidence of DGF, improving graftHBD recipients [35, 40]. Further, there seems to be no
function, and extending graft survival [64, 65]. UW isrelationship between WIT and patient survival when the
more expensive than EC, but in the longer term, the costsNHBD kidneys are analyzed as a group [27]. The overall
are more than recovered because of improved kidneyquality of life for recipients of NHBD organs is not
function [66]. Presently UW is considered the gold-stan-significantly different than that of recipients of HBD
dard preservative [61].organs or living-donor organs using the KD-QOL scoring
Histidine-tryptophan-ketoglutarate (HTK). HTK hassystem (Fig. 6) [18].
been shown to reduce the incidence of DGF [67, 68] andOne of the difficulties in comparing graft function,
its use results in higher rates of initial graft function andand graft and patient survival in NHBD and HBD are
graft survival than kidneys stored in EC solution [69].intergroup variations in WIT, causes of death, donor
However, experimental data suggest that UW is superiorage, HLA matching, in situ perfusion times, method of
to HTK in the preservation of ischemically damagedpreservation, and immune suppression protocols used.
kidneys [70].The variations make comparisons difficult and stress the
Celsior solution. This has a formulation similar to ex-need for studies of paired kidneys where possible.
tracellular fluid, with mannitol and lactobionate added
as impermeants. It has equal efficacy to UW in the con-
POTENTIAL FUTURE DEVELOPMENTS text of NHBD kidneys [62], but its clinical use is currently
Results from all modes of kidney transplantation are limited to cardiac preservation [61].
improving due to greater understanding of the mecha-
Machine preservation or static cold storage?nisms of ischemia/reperfusion injury and warm ischemic
damage, improved preservation techniques, develop- Preservation methods aim to limit the damage inflicted
ment of viability testing prior to implantation, and ad- by cold and warm ischemia, but as yet the optimum
vances in immune suppression. NHBD outcomes are method has not been determined. The two approaches
encouraging, and areas of research aimed at limiting or to preservation prior to transplant are cold storage and
partially reversing cold and warm ischemic damage, and machine perfusion. There is a significant body of research
limiting immune and nonimmune nephrotoxicity hold comparing these two techniques, but debate remains.
out hope for further expansion of the NHBD pool. Simplicity, lower cost and ease of transport make cold
storage the method of choice for the majority of renal
Preservation fluids transplant centers, and a number of studies have shown
The importance of optimal preservation is highlighted no advantage of machine perfusion over cold storage
for NHBD kidneys as these grafts are subject to the dual [71–74]. There is evidence suggesting machine perfusion
damaging processes of warm and cold ischemia. In an of kidneys gives superior preservation in terms of out-
elegant study on the effect of warm ischemia and cold come measures (principally delayed graft function) com-
storage on renal vasculature, Hansen et al [57] showed pared to cold storage. The data for this come mainly
from HBD kidneys [75–78]. The beneficial effect maythat neither warm ischemia insult alone nor cold storage
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Table 4. The advantages and disadvantages of machinebe mediated by the maintenance of near-physiologic con-
perfusion (MP) compared to cold storage (CS)
ditions. Machine perfusion is said to supply or regenerate prior to kidney transplantation [87]
metabolic substrates lost during warm ischemia [64], such
Advantages Disadvantagesas adenine nucleotides and glutathione [79, 80]. It main-
Lower incidence of DGF Higher cost in the short termatains intracellular pH and discharges waste, dilutes or
Continuous monitoring of Endothelial injury is possible
neutralizes catabolic substances [81], and decreases so- parameters during perfusion
Decreased intrarenal vasospasm Possibility of graft damagebdium-dependent tissue edema [82]. The improved histo-
Ability to provide metabolic support Logistically more complexlogic integrity may be related to improved perfusion of
during perfusion
the renal cortex microcirculation with clearing of red Potential for pharmacological Possible equipment failure
manipulationcells and catabolic products of ischemic metabolism [80].
These metabolic and physiologic benefits generate a re- a In the longer term, mechanical perfusion is thought to be cost effective in that
it reduces the financial burden incurred by additional dialysis [83]duction in posttransplant dialysis by lowering the inci-
b Over-perfusion can cause cellular swelling [135] which may lead to graft dam-
dence of posttransplant acute tubular necrosis, with age. Thus a pressure or time limit may need to be applied. Further, manipulation
of the renal artery for cannulation can cause endothelial damageshorter hospital stay and increased long-term allograft
survival. These benefits have been variously shown in
canine autotransplantation [83], an isolated perfused kid-
ney model [64], and in human renal transplantation study lies in the comparison of paired kidneys, but the
[84–86]. Light et al [81] reported 95% immediate func- numbers were small and different solutions were used
tion with mechanical perfusion for HBD kidneys com- for each group.
pared to the national figure of 75% for nonperfused In summary, mechanical perfusion appears to be bene-
kidneys [87], while Mendez et al [88] showed 65% of ficial only for NHBD kidneys and may not confer an advan-
mechanically perfused kidneys had immediate function tage for HBD kidneys [35, 93, 94]. Overall, it has been
compared to 34% of those treated with cold storage. suggested that mechanical perfusion reduces the cost of
There is a significant rise in the rate of acute tubular NHBD programs because of better initial function, shorter
necrosis if cold storage exceeds 24 to 30 hours, an effect
length of stay, decreased use of antibody preparations,
not seen in pulsatile-perfused kidneys [88]. Southard and
and fewer hemodialysis sessions [82, 83, 87] (Table 4).Belzer [89] reported only 18% acute tubular necrosis for
mechanically perfused NHBD kidneys compared to the Viability tests
reported rates of 70% to 100% for cold storage NHBD
One of the difficulties encountered in NHBD pro-kidneys. In a randomized comparison of paired HBD
grams is judging whether an organ is fit to transplant.kidneys, Alijani et al [78] found that dialysis require-
Successful expansion of the NHBD pool will in part bements posttransplantation were 63% for cold storage
reliant on accurate predictors of which kidneys shouldgrafts and 17% for mechanical perfusion grafts. The
be transplanted and which should not. The NHBD kid-power of this study lies in the exact matching of donor
neys that never develop function have sustained irrevers-criteria and explantation conditions. Despite this promis-
ible ischemic damage before transplantation, and thereing evidence, a number of prospective and retrospective
are currently no reliable pretransplantation tests of via-studies comparing mechanical perfusion with cold stor-
bility. A pretransplantation viability test needs to beage for HBD kidneys have not shown a benefit. No
simple, quick to perform, and have a high predictivedifference was found when comparing serum creatinine
value. The test should measure the potential for recovery[72], dialysis requirement [72, 73, 90, 91], graft survival
of the organ, rather than the amount of injury sustained.[72, 73, 88], or patient survival [72, 88].
Donor age, donor serum creatinine, and WIT. Of theDaemen, de Vries, and Oomen [92] found DGF and
donor history parameters, WIT is the only one that canPNF rates for machine-perfused NHBD kidneys were
discriminate between grafts that will function and thosehigher than those of the cold-stored HBD kidneys, sug-
that will not [95].gesting that mechanical perfusion cannot eliminate the
Macroscopic appearance at harvesting. Bell et al [51]inherent quality discrepancy between the two sources.
reported that one fourth of NHBD kidneys were rejectedHowever, there was a lower rate of DGF in perfused-
on the basis of visual inspection; this requires a goodNHBD kidneys than that reported elsewhere for cold-
deal of experience and the criteria are qualitative.stored NHBD kidneys [36, 40]. Matsuno et al [28] used
Nucleotide measurements. Anoxia uncouples the pro-paired kidneys from 13 controlled NHBDs and randomly
cess of cellular oxidative phosphorylation, resulting in aallocated them to cold storage or mechanical perfusion.
decrease in the levels of adenine nucleotides. NucleotideImmediate function was 35% in the mechanical perfu-
levels do decrease with warm and cold ischemia, butsion group compared to 8% in the cold storage group,
studies so far have shown that the levels are no use inwith 1-month graft survival of 100% for mechanical per-
fusion and 77% for cold storage. The strength of this predicting later outcome [96, 97].
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Perfusate lactate dehydrogenase Perfusate lactate de- to the long WITs. Polyak et al [101] used papaverine,
prostaglandin E1, trifluoperazine, and verapamil duringhydrogenase (LDH) [98] levels have been shown to be
directly related to degree of ischemia [99] and are an perfusion in an attempt to manipulate kidneys with low
flow and high resistance. Unresponsiveness to treatmentindictor of preservation damage [100]. The levels are
easily assayed, but LDH is relatively nonspecific, there- may indicate a poor-quality kidney. The weakness of all
of these studies is that there is no evidence that kidneysfore probably not useful for viability assessment [98].
Alpha glutathione S-transferase. Alpha glutathione discarded because of poor pump parameters alone would
fail to work adequately.S-transferase (-GST), a proximal tubular enzyme, and
-GST, a distal tubular enzyme, have been assessed as Viability scoring based on vascular parameters, oxida-
tive metabolism, and vascular condition demonstratesviability indicators [101]. -GST may be a marker of
damage, because it is released from the hypoxia-sensitive efficacy in predicting severity of acute tubular necrosis
and the occurrence of PNF [106]. It offers a sensitive assayproximal tubular cell and levels correlate with WIT.
There is no such correlation for -GST. Total GST, for prospective organ testing based on multiple values.
Proton magnetic resonance spectroscopy. The releaseas a predictor of functional recovery, was examined by
Balupuri et al [102]. After introduction of machine perfu- of phosphorus atoms occurs with the intracellular degra-
dation of adenosine triphosphate (ATP) to adenosine di-sion and total GST measurement, they increased their
success rate (% dialysis-free at 3 years) for NHBD from phosphate (ADP) and adenosine monophosphate (AMP).
There is a strong correlation between warm and cold45.5% to 92.3% by not transplanting kidneys that yielded
high levels of GST. ischemic damage (assessed by electron microscopy) and
the phosphorous monoester (PME) to inorganic phospho-Pressure, flow and resistance during machine preserva-
tion. These parameters, measured during machine pres- rous (Pi) ratio (PME/Pi) measured by magnetic resonance
spectroscopy (MRS). Viability is associated with highervation, are promising viability assessors, and the ap-
proach affords a number of advantages. First, the kidney intracellular levels of PME and low levels of Pi [107]. The
technique is noninvasive, nondestructive, sterile, rapid,may be resuscitated with machine perfusion. Second,
perfusate chemistry can be synchronously measured. and because it indirectly measures the metabolic compe-
tence of cells, it shows promise as a viability assessor [108].Third, there is potential for pharmacologic manipulation
of the organ while it is on the machine [101]. Ischemic The technique can also be applied to biofluids [109].
Most of these techniques of viability assessment haveinjury causes the release of vasoconstrictors from endo-
thelium; together with accumulation of erythrocytes and not yet proved to be reliable indicators of functional
outcome. Additionally, many of the data are from HBDmicrothrombosis, the result is diminished flow and in-
creased resistance [101]. Some authors have shown that kidneys and the relevance to NHBD kidneys is a theoret-
ical extrapolation. One of the difficulties of viability as-low intrarenal resistance and high flow alone are evi-
dence of viable kidneys [25, 28]. Matsuno et al [103] sessment is that the cold conditions of the kidney render
metabolic studies difficult to interpret. If oxidative me-found that perfusate flow was a reliable indicator of
viability based on early functional recovery of the kidney tabolism is restarted by perfusion in a more physiologic
setting, then parameters may be more meaningful. Thegraft; the higher the flow, the greater the level of immedi-
ate function. Tesi et al [104] rejected HBD kidneys if reinstatement of energy-dependent processes requires
metabolic substrates and an efficient oxygen carrier inflow was less than 70 mL/min or intrarenal resistance
was greater than 40 mL/min/100 g. With these criteria, the perfusate to prevent anaerobic metabolism; an area
of research to this end is the use of tissue culture–likethe posttransplant acute tubular necrosis rate was only
8.6%. Kozaki et al [105] stated the criteria for accepting fluid with an added perflurocarbon. The tissue culture
fluid contains more than 70 ingredients, including aminoa kidney on the basis of vascular parameters were (1) a
minimum flow rate of 40 mL/min/100 g at 50 mm Hg acids, lipids, carbohydrates, proteins, trophic factors, va-
sodilators, and adenine compound substrates, adjustedpressure, and (2) an increasing perfusion volume and
decreasing or plateauing pressure during perfusion, to normal pH. The perflurocarbon [110] displays a linear
oxygen dissociation relationship. Using this perfusate atwhile Balupuri et al [102] suggested accepting only those
kidneys with a flow rate of no less than 50mL/min/100 30C to 32C, Stubenitsky et al [111] showed lower oxy-
gen consumption, glucose consumption, urine flow, andg at a perfusion pressure of 60 mm Hg. Their results were
so encouraging, they suggested that not using machine glomerular filtration rate (GFR), with increasing warm
ischemic time in ex vivo kidneys. There was a strongperfusion for NHBD was difficult to justify. Even kidneys
with long WITs (up to 140 minutes) that have an accept- correlation between the latter two parameters and histo-
logic grading of acute tubular necrosis, suggesting warmable flow on machine perfusion can function well when
transplanted [28, 29]. This stresses the importance of the perfusion may be a valuable predictive tool. These en-
couraging results may be due to restoration of renalkidneys’ behavior on the machine as a viability predictor;
such kidneys would have otherwise been discarded due metabolism, presumably a safe procedure if the correct
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environment is applied. For the present time, it remains without any deleterious effects on renal function or sur-
vival [119]. A further study has demonstrated reduceda fact that the only accurate way to predict graft function
rates of acute rejection in patients with delayed graftis to transplant the organ.
function treated with daclizumab [120]. No data have
Immune suppression for NHBD kidneys yet been published for the use of interleukin-2 (IL-2)
receptor antibodies in NHBD kidneys.A number of immunosuppressive strategies have been
Delayed graft function is so high in NHBD, presum-employed for NHBD kidney recipients. Triple therapy
ably due to warm ischaemia, but data have shown equiva-with cyclosporine A (CsA), prednisolone, and azathio-
lence in terms of graft survival for HBD and NHBD [15,prine, or quadruple therapy with the addition of antilym-
35, 40]. Thus, the aim of tailoring immunosuppressionphocyte globulin (ALG) have been the most commonly
for NHBD should be to reduce the need for dialysisused protocols [3, 30, 55, 94, 112]. Nonrandomized stud-
treatment during this time and avoid the episodes ofies of controlled NHBD have compared acute rejection
acute rejection that occur more commonly during DGF.and graft survival rates in groups treated with tacrolimus
or CsA [113, 114]. The tacrolimus group had lower rates Technical approaches
of acute rejection and DGF, but there was no difference
In situ cooling reduces renal oxygen consumption andin long-term graft survival. As yet there is no clear advan-
thereby prevents accumulation of the products of anaer-tage of one calcineurin inhibitor over another, and further
obic metabolism. The technique of kidney cooling priordata are required. The dose-dependent acute and chronic
to retrieval should be easy to initiate, provide reliablenephrotoxic effects of calcineurin inhibitors are well de-
hypothermia, and be acceptable to relatives of the donor.scribed [115, 116]. Apart from chronic allograft nephrop-
There are three approaches.athy (CAN), one of the main problems of calcineurin
Intravascular cooling. This is the simplest and mostinhibitors is that toxicity masks acute rejection episodes.
popular method and has been described earlier in thisSome centers avoid the immediate posttransplant expo-
paper. Recent developments include the incorporationsure to calcineurin inhibitors by using antibody induction
of secondary control balloons, allowing the surgeon totherapy (ALG or OKT3), adding a calcineurin inhibitor
be certain the main balloons are correctly inflated. Thereonce the serum creatinine has fallen. [2, 3, 35]. Schlumpf
is now a four-lumen catheter that allows continuous pres-et al [43] reported very good 1-year graft survival and
sure monitoring so that flush pressures are maintained atfunction using ALG rather than early CsA in controlled
approximately 70 mm Hg; there is evidence that cortical
NHBD. Kinukawa et al [3] performed a nonrandomized perfusion is most effective at this pressure [121].
study of high-dose CsA plus prednisolone versus low- Extracorporeal total-body cooling. Here, oxygenated
dose CsA with prednisolone plus ALG for the first 14 and cooled blood is used to perfuse the whole body by
days in controlled NHBDs. Outcomes for early function means of extracorporeal circulation equipment [7, 9, 13,
and graft survival to 60 months were significantly better 122–124]. Temperature is monitored using an oesopha-
in the low-dose CsA group. Asano et al [117] performed geal monitor, with a target temperature of 15C to 18C.
a similar study with these two experimental groups and The potential advantage is that the NHBD can be main-
a further one using low-dose CsA, prednisolone, and aza- tained on bypass for long periods while awaiting consent.
thioprine, and found that this third group had even better However, it is a complex technique requiring the expertise
outcomes than the ALG group. Using quadruple therapy of a perfusionist. Recently, Valero, Catiana, and Oppen-
of low-dose CsA, prednisolone, azathioprine, and ALG heimer [125] have shown that normothermic perfusion
[4], better results have been obtained for NHBD kidneys with cardiopulmonary bypass results in lower rates of pri-
than with other regimens involving normal doses of CsA. mary nonfunction and lower rates and shorter duration
The monoclonal antibody OKT3 has been used for of delayed graft function for NHBD kidneys than those
induction therapy, but it has a broad side-effect profile. preserved with either intravascular or total body cooling.
In one study, 6 of 17 uncontrolled NHBD recipients Intraperitoneal cooling alone or combined with intra-
treated with OKT3 developed neurologic complications, vascular cooling. With this technique a chest tube is in-
half of who required temporary mechanical ventilation serted into the abdomen through a supraumbilical incision
for respiratory support [118]. [25]; the organs are cooled and emergency laparotomy
Mycophenolate mofetil (MMF) and rapamycin are two is performed to extract the kidneys. The method was
newer immunosuppressants that are nonnephrotoxic, with developed further by Light et al [126]. By using a closed
potential to replace calcineurin inhibitors in the longer recirculating system for intraperitoneal cooling and sub-
term. The authors’ unit now uses low-dose tacrolimus zero temperature fluids (50/50 alcohol and ice water),
for NHBDs, plus MMF and prednisolone. Daclizumab, they were able to reduce the inferior vena cava tempera-
a humanized monoclonal anti-IL2 antibody, is a drug of ture to 10C in 60 minutes. After transplantation, their
emerging potential. In phase III clinical trials, it has been DGF rates were only 50%, compared to other authors
shown to reduce the incidence of acute rejection at 6 and who had rates of up to 100% for NHBD kidneys cooled
with the intravascular technique [36, 40].12 months after primary cadaveric renal transplantation,
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ETHICS AND LEGAL ISSUES Clearly, these ethical issues are very important and need
to evolve along with changes in public opinion. WhileThe principal ethical issues concerning NHBD pro-
attempting to increase available organs for chronicallygrams are the use of in situ perfusion prior to consent,
ill patients, there is potential for public misunderstandingthe diagnosis of death by cardiac rather than brain-stem
of NHBD programs; Caplan [132] suggested this couldcriteria, and at what time after pronouncement of death
result in a paradoxical decrease in all donations.the in situ cooling should be started (the “dead donor
rule”). Careful thought and constant reassessment needs
to be given to ethical and legal guidelines, so donation CONCLUSION
can be increased while respecting public concerns. There
NHBD kidneys have the potential to expand the donoris considerable variation in the laws of different countries
pool but need to gain wider acceptance amongst trans-with regards transplantation, and specifically NHBD
plant personnel, many of whom are unconvinced of theirprocurement [127–129]. Further, within a country there
benefits. The principal concerns are that NHBD kidneysmay be regional differences dependant on the coroner
do not function as well as those from other sources.and local ethics committee guidelines. English law does
While PNF and DGF are higher in the NHBD, there isnot require consent for prolonged ventilator support or
no evidence that renal function, graft and patient sur-placement of the DBTL catheter, but catheter placement
vival, or quality of life are compromised. There are alsois an invasive procedure and the family members may
concerns about ethics and the burdens of cost and timenot wish for this. The counter-argument is that by placing
associated with adopting and running NHBD programs.the catheter and preserving kidneys, more families are
There is firm evidence that these programs maintaingiven the opportunity to donate [13]. For ideal preserva-
donation rates at a time when other sources are failing totion, the kidneys should be perfused as soon as the 10-
adequately contribute to the donor pool. Developmentsminute waiting period is over. There is then more time
toward ideal preservation conditions are being made,for a careful discussion with relatives and time for them
while techniques of viability assessment will help avoidto reach a considered decision. Relatives’ consent for the
transplantation of kidneys that will never function. Tai-actual donation is always taken, regardless of evidence of
loring of immune suppression for NHBDs, with minimi-the potential donor’s wishes antemortem. It has been
zation of nephrotoxicity, may further improve results.found that obtaining consent in two stages may result in
refusal of consent for nephrectomy after initially gaining
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